AU3716193A - Pharmaceutical compositions - Google Patents

Pharmaceutical compositions

Info

Publication number
AU3716193A
AU3716193A AU37161/93A AU3716193A AU3716193A AU 3716193 A AU3716193 A AU 3716193A AU 37161/93 A AU37161/93 A AU 37161/93A AU 3716193 A AU3716193 A AU 3716193A AU 3716193 A AU3716193 A AU 3716193A
Authority
AU
Australia
Prior art keywords
pharmaceutical compositions
pharmaceutical
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU37161/93A
Inventor
Not Given Name
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of AU3716193A publication Critical patent/AU3716193A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
AU37161/93A 1992-05-20 1993-04-23 Pharmaceutical compositions Abandoned AU3716193A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CH1619/92 1992-05-20
CH161992 1992-05-20
CH926/93 1993-03-26
CH92693 1993-03-26

Publications (1)

Publication Number Publication Date
AU3716193A true AU3716193A (en) 1993-11-25

Family

ID=25686129

Family Applications (1)

Application Number Title Priority Date Filing Date
AU37161/93A Abandoned AU3716193A (en) 1992-05-20 1993-04-23 Pharmaceutical compositions

Country Status (12)

Country Link
EP (1) EP0579915A1 (en)
JP (1) JPH0632740A (en)
KR (1) KR940005278A (en)
CN (1) CN1080525A (en)
AU (1) AU3716193A (en)
CA (1) CA2096196A1 (en)
CZ (1) CZ83293A3 (en)
HU (1) HUT66864A (en)
IL (1) IL105700A0 (en)
NO (1) NO931831L (en)
NZ (1) NZ247630A (en)
TW (1) TW272187B (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6461622B2 (en) * 1994-09-07 2002-10-08 Johnson & Johnson Consumer Companies, Inc. Topical compositions
DK128494A (en) * 1994-11-08 1996-05-09 Edel K Seidenschnur Treatment of keratinous and psoriatic disease states with nail polish containing vitamin D metabolite, or derivative, and / or vitamin A derivative
US5837728A (en) * 1995-01-27 1998-11-17 Molecular Design International 9-cis retinoic acid esters and amides and uses thereof
AU6944796A (en) * 1995-09-28 1997-04-17 Teijin Limited Preventive or remedy for hyperthyreosis
US5716946A (en) * 1996-02-13 1998-02-10 Wisconsin Alumni Research Foundation Multiple sclerosis treatment
CA2209205A1 (en) * 1996-07-01 1998-01-01 Nisshin Flour Milling Co., Ltd. Pharmaceutical composition for the treatment of leukemia containing 9-cis-retinoic acid-alpha-tocopherol ester
US5891865A (en) * 1996-10-04 1999-04-06 Wisconsin Alumni Research Foundation Treatment of arthritic disease induced by infectious agents
FR2767058B1 (en) * 1997-08-05 2000-05-05 Centre Nat Rech Scient USE OF A RETINOID-LIKE COMPOUND, IN PARTICULAR RETINOIC ACID FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF OBESITY.
EP0908179A1 (en) * 1997-08-23 1999-04-14 Werner Bollag Treatment of cell-mediated immune diseases
US8541469B2 (en) 1997-08-23 2013-09-24 Glaxo Group Limited Treatment of cell-mediated immune diseases
US6552009B2 (en) 1998-07-16 2003-04-22 Gentrix Llc Compositions and methods of treating abnormal cell proliferation
US20010002396A1 (en) 1998-07-16 2001-05-31 Charles Achkar Compositions and methods of treating skin conditions
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6479474B2 (en) 1999-07-08 2002-11-12 Wisconsin Alumni Research Foundation Dietary calcium as a supplement to vitamin D compound treatment of multiple sclerosis
US6733779B2 (en) * 1999-08-26 2004-05-11 L. Dean Parks Method of treating benign prostatic hyperplasia and other benign prostate conditions
FR2807662A1 (en) * 2000-04-12 2001-10-19 Cll Pharma PROCESS FOR STABILIZING THE SIZE OF AN ACTIVE INGREDIENT DISPERSE IN A LIQUID AND ITS APPLICATIONS
US6339107B1 (en) 2000-08-02 2002-01-15 Syntex (U.S.A.) Llc Methods for treatment of Emphysema using 13-cis retinoic acid
JP2002104995A (en) * 2000-09-29 2002-04-10 Masahiko Hosaka Telomerase activity inhibitor
JP4326159B2 (en) 2001-02-09 2009-09-02 株式会社ジェイテクト Ball bearing
WO2004098612A2 (en) * 2003-05-07 2004-11-18 Ab Science Calcitriol analogs of uses thereof
BRPI0410646A (en) * 2003-05-20 2006-07-04 Ranbaxy Lab Ltd Acitretin pharmaceutical compositions and process for their preparation
WO2005102296A2 (en) * 2004-04-23 2005-11-03 Heptagen Limited Combinations for the treatment of immunoproliferative skin disorders such as psoriasis
CN102727476B (en) * 2012-06-14 2014-05-14 合肥博太医药生物技术发展有限公司 Application of retinoic acid and its derivatives in preparation of drugs preventing and treating osteoporosis
JP2019014676A (en) * 2017-07-06 2019-01-31 東海カプセル株式会社 Capsule agent

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6360910A (en) * 1986-09-01 1988-03-17 Shiseido Co Ltd Skin drug for external use

Also Published As

Publication number Publication date
HU9301404D0 (en) 1993-09-28
IL105700A0 (en) 1993-09-22
NO931831D0 (en) 1993-05-19
HUT66864A (en) 1995-01-30
CZ83293A3 (en) 1993-12-15
NO931831L (en) 1993-11-22
JPH0632740A (en) 1994-02-08
TW272187B (en) 1996-03-11
KR940005278A (en) 1994-03-21
CN1080525A (en) 1994-01-12
NZ247630A (en) 1995-12-21
EP0579915A1 (en) 1994-01-26
CA2096196A1 (en) 1993-11-21

Similar Documents

Publication Publication Date Title
ZA938825B (en) Pharmaceutical compositions
GB9209078D0 (en) Pharmaceutical compositions
AU3716193A (en) Pharmaceutical compositions
GB9317686D0 (en) Pharmaceutical compositions
AU5100393A (en) Diindolo compounds and pharmaceutical compositions containing them
GB9317610D0 (en) Pharmaceutical compositions
AU3542993A (en) Pharmaceutical compounds
AU2392492A (en) Pharmaceutical composition
GB9209874D0 (en) Pharmaceutical compositions
GB9317504D0 (en) Pharmaceutical compositions
AU5294393A (en) Topical pharmaceutical compositions
AU2537992A (en) Pharmaceutical compositions
GB9226377D0 (en) Pharmaceutical compositions
AU1544195A (en) Pharmaceutical compositions
AU1427895A (en) Pharmaceutical compositions
HU9401771D0 (en) Pharmaceutical compositions cintaining ipsapiron
GB9211276D0 (en) Pharmaceutical compositions
AU3528593A (en) Pharmaceutical composition
AU7135091A (en) Pharmaceutical composition
GB9420129D0 (en) Pharmaceutical compositions
AU673835C (en) Medicinal composition comprising TCF-II
AU9016891A (en) Pharmaceutical compositions
AUPM303393A0 (en) Pharmaceutical composition
GB9321452D0 (en) Pharmaceutical compositions
GB9221447D0 (en) Pharmaceutical compositions